FIPI

FIPI is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function[1][2][3][4].

Product Specifications

CAS Number

[939055-18-2]

Product Name Alternative

5-Fluoro-2-indolyl deschlorohalopemide

UNSPSC

12352005

Target

Phospholipase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/FIPI.html

Purity

98.00

Solubility

DMSO : 3.33 mg/mL (ultrasonic)

Smiles

O=C(NCCN1CCC(CC1)N2C3=CC=CC=C3NC2=O)C4=CC5=C(C=CC(F)=C5)N4

Molecular Formula

C23H24FN5O2

Molecular Weight

421.47

References & Citations

[1]Su W, et al. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol. 2009 Mar;75 (3) :437-46.|[2]Stricker HM, et al. The phospholipase D inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells. Cell Commun Signal. 2021 Apr 8;19 (1) :43.|[3]Elvers M, et al. A novel role for phospholipase D as an endogenous negative regulator of platelet sensitivity. Cell Signal. 2012 Sep;24 (9) :1743-52. |[4]Stegner D, et al. Pharmacological inhibition of phospholipase D protects mice from occlusive thrombus formation and ischemic stroke--brief report. Arterioscler Thromb Vasc Biol. 2013 Sep;33 (9) :2212-7.